Loading InvisibleSignal...

Insurance Coverage Gap Analysis

Identifying where patients with invisible illnesses fall through insurance coverage cracks

Denied Initial Claims

67%of patients

Avg Out-of-Pocket

$12,400/year

Appeals per Patient

3.2average

Lose Coverage

42%of patients

Coverage Denial Rates by Condition

Percentage of insurance claims denied for common invisible illness treatments and diagnostic services

Lyme Disease (extended)

72% denied

ME/CFS

68% denied

POTS testing

61% denied

Alpha-gal (specialty)

58% denied

Fibromyalgia

54% denied

Long COVID rehab

47% denied

Common Denial Reasons

Most frequent reasons insurers cite when denying claims for invisible illness treatments, and corresponding appeal success rates

Code	Denial Reason	Frequency	Appeal Success
M-NM	Not medically necessary	38%	45% success
EXP-I	Experimental/investigational	24%	32% success
OON	Out-of-network provider	18%	67% success
PA-NO	Prior authorization not obtained	12%	78% success
LIMIT	Exceeds visit/treatment limits	8%	41% success

Claims denied as “not medically necessary” account for 38% of all denials, yet evidence-based treatment guidelines support these treatments. Prior authorization denials have the highest appeal success rate (78%) when proper documentation is submitted retroactively.

Out-of-Pocket Burden

Average annual out-of-pocket spending breakdown for invisible illness patients after insurance

Specialists

$4,200

Labs & Testing

$2,800

Medications

$2,400

Supplements

$1,600

Travel for Care

$1,400

Total Annual Out-of-Pocket$12,400/yr

Insurance Type Comparison

How different insurance types cover key services for invisible illness patients

Insurance Type	Specialist Access	Extended Treatment	Lab Coverage	Mental Health	Alternative Therapy
Employer-Sponsored	Good	Partial	Good	Good	Poor
ACA Marketplace	Partial	Partial	Partial	Good	Poor
Medicare	Good	Partial	Good	Partial	None
Medicaid	Partial	Poor	Partial	Partial	None
TRICARE	Good	Partial	Good	Good	Partial

No insurance type provides consistently good coverage across all service categories for invisible illness patients. Alternative therapy coverage remains the largest gap across all plans, despite many patients relying on integrative treatments when conventional options are exhausted.

State-Level Protections

States with Lyme-specific insurance laws, surprise billing protections, and related patient safeguards

State	Lyme Insurance Law	Surprise Billing	Notes
CT	Yes	Yes	First state to mandate Lyme coverage (1999)
MA	Yes	Yes	Long-term antibiotic coverage required
RI	Yes	Yes	Mandates coverage for Lyme treatment
MN	Yes	Yes	Insurance cannot deny Lyme treatment
NY	Yes	Yes	Tick-borne disease coverage mandate
ME	Yes	Limited	Physician discretion for treatment duration
NH	Yes	Yes	Coverage for clinical diagnosis
PA	No	Yes	Lyme legislation pending
VA	No	Yes	No Lyme-specific mandate
TX	No	Yes	Surprise billing protections only

Only 7 states have Lyme-specific insurance mandates. The federal No Surprises Act (2022) provides baseline surprise billing protections, but state-level laws often offer stronger patient safeguards. Patients should check their state insurance commissioner's website for specific protections.

Appeal Strategies

Step-by-step process for challenging insurance denials, including external review rights and regulatory complaint options

Internal Appeal (Level 1)

File within 180 days of denial. Include treating physician's letter of medical necessity, peer-reviewed studies, and detailed treatment notes.

30 days for response

Internal Appeal (Level 2)

Request review by a different medical director. Submit additional documentation, specialist opinions, and any new diagnostic results.

30 days for response

External Review

Federal law guarantees the right to an independent, external review. The reviewer is not employed by your insurer and their decision is binding.

45 days for standard, 72 hours for urgent

State Insurance Commissioner

File a formal complaint with your state's Department of Insurance. This creates a regulatory record and may trigger an investigation into the insurer's practices.

Varies by state (30-90 days typical)

Legal Action / Advocacy

Contact patient advocacy organizations (LymeDisease.org, Solve ME/CFS). Consider consulting a health insurance attorney for ERISA or bad faith claims.

As needed

Key fact: Studies show that 50-60% of appealed denials are overturned, yet fewer than 1% of denied claims are ever appealed. Always appeal a denial — the odds are in your favor.

Policy Recommendations

Systemic changes needed to improve insurance coverage for invisible illness patients

AMA CPT Code Updates

Create specific CPT codes for extended Lyme disease treatment protocols
Add codes for post-infectious syndrome rehabilitation services
Develop telehealth-specific codes for chronic illness management

ICD-10 Coding Improvements

Expand A69.2x subcategories for chronic/persistent Lyme manifestations
Add specificity to G93.32 (ME/CFS) for severity staging
Create distinct codes for alpha-gal syndrome severity levels
Improve Long COVID coding to capture rehabilitation needs

Parity Legislation

Federal Lyme disease insurance coverage mandate (parity with other infections)
Require insurers to cover treatments recommended by treating physicians
Eliminate 'experimental' classification for established treatment protocols
Mandate coverage of specialty testing (e.g., alpha-gal panels, tilt table tests)

Explore Related Modules

Insurance Navigator

Coverage & appeals guide

Disability Guide

SSDI/SSI & legal protections

Advocacy Toolkit

Patient rights & letter templates

Policy Intelligence

Billing gaps & recommendations

Data Sources (7)

KFF (Kaiser Family Foundation). Claims Denial and Appeal Rates in ACA Marketplace Plans. 2024.
Commonwealth Fund. Health Insurance Coverage and Access to Care for People with Chronic Conditions. 2023.
National Conference of State Legislatures (NCSL). State Insurance Mandates for Tick-Borne Diseases. 2024.
AHRQ Medical Expenditure Panel Survey. Patient Out-of-Pocket Costs and Financial Hardship. 2023.
Johns Hopkins Bloomberg School of Public Health. Economic Burden of Lyme Disease. 2023.
CMS. No Surprises Act Implementation Data. 2024.
Georgetown University Health Policy Institute. External Review Outcomes in Health Insurance Appeals. 2023.

Disclaimer

Insurance coverage data is based on published research, insurance claims databases, and patient surveys. Denial rates and appeal outcomes vary by insurer, plan type, state, and individual circumstances. State law information is current as of 2024 but may have changed. This tool is for informational and advocacy purposes only and does not constitute legal or insurance advice. Consult a qualified health insurance advocate or attorney for guidance on your specific situation.

Insurance Coverage Gap Analysis

Identifying where patients with invisible illnesses fall through insurance coverage cracks

Denied Initial Claims

67%of patients

Avg Out-of-Pocket

$12,400/year

Appeals per Patient

3.2average

Lose Coverage

42%of patients

Coverage Denial Rates by Condition

Percentage of insurance claims denied for common invisible illness treatments and diagnostic services

Lyme Disease (extended)

72% denied

ME/CFS

68% denied

POTS testing

61% denied

Alpha-gal (specialty)

58% denied

Fibromyalgia

54% denied

Long COVID rehab

47% denied

Common Denial Reasons

Most frequent reasons insurers cite when denying claims for invisible illness treatments, and corresponding appeal success rates

Code	Denial Reason	Frequency	Appeal Success
M-NM	Not medically necessary	38%	45% success
EXP-I	Experimental/investigational	24%	32% success
OON	Out-of-network provider	18%	67% success
PA-NO	Prior authorization not obtained	12%	78% success
LIMIT	Exceeds visit/treatment limits	8%	41% success

Out-of-Pocket Burden

Average annual out-of-pocket spending breakdown for invisible illness patients after insurance

Specialists

$4,200

Labs & Testing

$2,800

Medications

$2,400

Supplements

$1,600

Travel for Care

$1,400

Total Annual Out-of-Pocket$12,400/yr

Insurance Type Comparison

How different insurance types cover key services for invisible illness patients

Insurance Type	Specialist Access	Extended Treatment	Lab Coverage	Mental Health	Alternative Therapy
Employer-Sponsored	Good	Partial	Good	Good	Poor
ACA Marketplace	Partial	Partial	Partial	Good	Poor
Medicare	Good	Partial	Good	Partial	None
Medicaid	Partial	Poor	Partial	Partial	None
TRICARE	Good	Partial	Good	Good	Partial

State-Level Protections

States with Lyme-specific insurance laws, surprise billing protections, and related patient safeguards

State	Lyme Insurance Law	Surprise Billing	Notes
CT	Yes	Yes	First state to mandate Lyme coverage (1999)
MA	Yes	Yes	Long-term antibiotic coverage required
RI	Yes	Yes	Mandates coverage for Lyme treatment
MN	Yes	Yes	Insurance cannot deny Lyme treatment
NY	Yes	Yes	Tick-borne disease coverage mandate
ME	Yes	Limited	Physician discretion for treatment duration
NH	Yes	Yes	Coverage for clinical diagnosis
PA	No	Yes	Lyme legislation pending
VA	No	Yes	No Lyme-specific mandate
TX	No	Yes	Surprise billing protections only

Appeal Strategies

Step-by-step process for challenging insurance denials, including external review rights and regulatory complaint options

Internal Appeal (Level 1)

File within 180 days of denial. Include treating physician's letter of medical necessity, peer-reviewed studies, and detailed treatment notes.

30 days for response

Internal Appeal (Level 2)

Request review by a different medical director. Submit additional documentation, specialist opinions, and any new diagnostic results.

30 days for response

External Review

Federal law guarantees the right to an independent, external review. The reviewer is not employed by your insurer and their decision is binding.

45 days for standard, 72 hours for urgent

State Insurance Commissioner

File a formal complaint with your state's Department of Insurance. This creates a regulatory record and may trigger an investigation into the insurer's practices.

Varies by state (30-90 days typical)

Legal Action / Advocacy

Contact patient advocacy organizations (LymeDisease.org, Solve ME/CFS). Consider consulting a health insurance attorney for ERISA or bad faith claims.

As needed

Key fact: Studies show that 50-60% of appealed denials are overturned, yet fewer than 1% of denied claims are ever appealed. Always appeal a denial — the odds are in your favor.

Policy Recommendations

Systemic changes needed to improve insurance coverage for invisible illness patients

AMA CPT Code Updates

Create specific CPT codes for extended Lyme disease treatment protocols
Add codes for post-infectious syndrome rehabilitation services
Develop telehealth-specific codes for chronic illness management

ICD-10 Coding Improvements

Expand A69.2x subcategories for chronic/persistent Lyme manifestations
Add specificity to G93.32 (ME/CFS) for severity staging
Create distinct codes for alpha-gal syndrome severity levels
Improve Long COVID coding to capture rehabilitation needs

Parity Legislation

Federal Lyme disease insurance coverage mandate (parity with other infections)
Require insurers to cover treatments recommended by treating physicians
Eliminate 'experimental' classification for established treatment protocols
Mandate coverage of specialty testing (e.g., alpha-gal panels, tilt table tests)

Explore Related Modules

Insurance Navigator

Coverage & appeals guide

Disability Guide

SSDI/SSI & legal protections

Advocacy Toolkit

Patient rights & letter templates

Policy Intelligence

Billing gaps & recommendations

Data Sources (7)

KFF (Kaiser Family Foundation). Claims Denial and Appeal Rates in ACA Marketplace Plans. 2024.
Commonwealth Fund. Health Insurance Coverage and Access to Care for People with Chronic Conditions. 2023.
National Conference of State Legislatures (NCSL). State Insurance Mandates for Tick-Borne Diseases. 2024.
AHRQ Medical Expenditure Panel Survey. Patient Out-of-Pocket Costs and Financial Hardship. 2023.
Johns Hopkins Bloomberg School of Public Health. Economic Burden of Lyme Disease. 2023.
CMS. No Surprises Act Implementation Data. 2024.
Georgetown University Health Policy Institute. External Review Outcomes in Health Insurance Appeals. 2023.

Disclaimer